Histogen Inc (HSTO)
0.15
-0.05
(-25.00%)
USD |
OTCM |
May 03, 16:00
Histogen Revenue (TTM): 0.019M for Sept. 30, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | 0.019M |
| June 30, 2023 | 0.019M |
| March 31, 2023 | 0.019M |
| December 31, 2022 | 3.769M |
| September 30, 2022 | 3.77M |
| June 30, 2022 | 4.356M |
| March 31, 2022 | 4.356M |
| December 31, 2021 | 0.919M |
| Date | Value |
|---|---|
| September 30, 2021 | 1.392M |
| June 30, 2021 | 1.296M |
| March 31, 2021 | 1.399M |
| December 31, 2020 | 2.059M |
| September 30, 2020 | 3.142M |
| June 30, 2020 | 2.961M |
| March 31, 2020 | 4.128M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.019M
Minimum
Mar 2023
4.356M
Maximum
Mar 2022
2.240M
Average
2.059M
Median
Dec 2020
Revenue (TTM) Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.202M |
| IGC Pharma Inc | 1.216M |
| NovaBay Pharmaceuticals Inc | 14.73M |
| Protalix BioTherapeutics Inc | 65.49M |